Albert Schweitzer Ziekenhuis
- Address
- Langeweg 336, 3331 LZ Zwijndrecht, The Netherlands
Cardiovascular and Metabolic Research
At Albert Schweitzer Ziekenhuis, clinical research in Internal Medicine focuses on cardiovascular diseases and nutritional and metabolic diseases, with a strong emphasis on lipid disorders that can raise long-term heart risk.
- Studies in hypertriglyceridemia and severe hypertriglyceridemia
- Research on atherosclerotic cardiovascular disease and related blood vessel disease
- Trials designed to test new treatments and assess their impact on triglyceride levels and cardiovascular outcomes
This work aims to improve control of abnormal blood fats and better understand how treatment may reduce the risk of serious heart and circulation events.
Heart Risk Reduction Studies
The site is also involved in trials addressing atherosclerosis and broader cardiovascular disease, where the main goal is to evaluate whether new therapies can lower the chance of major complications.
- Focus on preventing major adverse cardiovascular events such as heart attack and stroke
- Investigation of treatment effectiveness in people whose current lipid-lowering care is not enough
- Clinical research centered on better management of artery narrowing caused by plaque buildup
These studies help clarify whether emerging therapies can offer added protection for people at elevated cardiovascular risk.
Lipid Disorder Treatment Research
Clinical trials at Albert Schweitzer Ziekenhuis include work on congenital, hereditary, and neonatal diseases and abnormalities as part of the broader effort to understand inherited patterns that may influence lipid abnormalities and heart health.
- Evaluation of therapies for triglyceride reduction
- Research involving people with inherited or persistent lipid disorders
- Efforts to improve treatment options for patients with difficult-to-control blood fat levels
Overall, the research seeks to support more effective and personalized care for patients living with complex metabolic and cardiovascular conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Ionis Pharmaceuticals Inc.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Albert Schweitzer Ziekenhuis
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Obicetrapib on Major Adverse Cardiovascular Events in Atherosclerotic Cardiovascular Disease Patients on Maximal Lipid-Modifying Therapy | NewAmsterdam Pharma B.V. | Phase III | Not Recruiting | May 2022 | — |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Isis 678354 Sodium Salt | 2 | Unknown | 2023-05-17 | 2023-06-08 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.